| Literature DB >> 35634335 |
Yongbo Wang1,2, Xingyu Liu1,2, Panpan Xia1, Zhangwang Li2, Xinxi FuChen1, Yunfeng Shen1, Peng Yu1, Jing Zhang3.
Abstract
An effective acute inflammatory response results in the elimination of infectious microorganisms, followed by a smooth transition to resolution and repair. During the inflammatory response, neutrophils play a crucial role in antimicrobial defense as the first cells to reach the site of infection damage. However, if the neutrophils that have performed the bactericidal effect are not removed in time, the inflammatory response will not be able to subside. Anti-inflammatory macrophages are the main scavengers of neutrophils and can promote inflammation towards resolution. MicroRNAs (miRNAs) have great potential as clinical targeted therapy and have attracted much attention in recent years. This paper summarizes the involvement of miRNAs in the process of chronic diseases such as atherosclerosis, rheumatoid arthritis and systemic lupus erythematosus by regulating lipid metabolism, cytokine secretion, inflammatory factor synthesis and tissue repair in two types of cells. This will provide a certain reference for miRNA-targeted treatment of chronic diseases.Entities:
Keywords: chronic disease; immunity; macrophages; miRNA; neutrophils
Mesh:
Substances:
Year: 2022 PMID: 35634335 PMCID: PMC9130478 DOI: 10.3389/fimmu.2022.901166
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 8.786
Figure 1Neutrophil Death under Harmful Stimulation. Neutrophils recognize pathogens through pattern recognition receptors (PRRs). The main PRRs are Toll-like receptors (TLR) or NOD-like receptors (NLR), and there are some other PRRs, such as scavenger receptors (SR). These PRRs can recognize pathogens in the extracellular cytoplasm and endosomes. Neutrophils are activated after recognizing the pathogen and begin to kill the pathogen. The final outcome of an inflammatory environment is often: necrosis, pyroptosis, and neutrophils external traps. These death pathways have different characteristics, but all exacerbate the inflammatory response.
Figure 2miRNA-mediated regulation of inflammatory factors by NET released in neutrophils. Under the influence of the vascular inflammatory environment, neutrophils, for example, mature macrophages release exosome-loaded miR-146, which stimulates neutrophil development and maturation to form NETs. The NETs supernatant contains miRNA, such as miR-142-3p. miR-142-3p targets macrophages to release more pro-inflammatory factors, which in turn accelerate the formation of a pro-inflammatory environment.
miRNAs regulate neutrophil-involved chronic diseases.
| miRNA | Expression level | Target | Function | Chronic diseases | Ref. |
|---|---|---|---|---|---|
| miR-21 | ↑ | PGE 2/IL-10 | pro-inflammation | sepsis | ( |
| miR-223-3p | ↓ | MKNK1 | pro-inflammation | sepsis | ( |
| miR-146a | ↑ | NF-κB | pro-inflammation | sepsis | ( |
| SOD2 | promote NETosis | ||||
| miR-887-3p | ↑ | IL-1β | pro-inflammation | sepsis | ( |
| VCAM-1 | |||||
| miR-155 | ↑ | NF-κB | pro-inflammation | sepsis | ( |
| miR-let-7b | ↑ | TLR4 | anti-inflammation | sepsis | ( |
| NF-κB | |||||
| miR-223 | ↑ | NLRP3/IL-1β | anti-inflammation | asthma | ( |
| hsa-miR-223-3p | ↑ | TLR/Th17 | endoplasmic reticulum stress | asthma | ( |
| miR-199a-5p | ↑ | WNT2 | inhibit lung regeneration | asthma | ( |
| WNT4 | |||||
| miR-629-3p | ↑ | IL-8 | pro-inflammation | asthma | ( |
| miR-4512 | ↓ | TLR4 | promote NETosis | SLE | ( |
| CXCL2 | |||||
| miR-let-7b | ↑ | TLR-7 | pro-inflammation | SLE | ( |
| miR-125a | ↓ | IL-16 | pro-inflammation | SLE | ( |
| miR-223-3p | ↑ | GM-CSF | anti-inflammation | COPD | ( |
| TRAF4 | |||||
| miR-1285 | ↑ | SP11 | pro-inflammation | IBD | ( |
| inhibit tissue repair | |||||
| miR-23a | ↑ | Lamin B1 | inhibit tissue repair | IBD | ( |
| miR-155 | RAD51 | pro-inflammation | |||
| miR-223 | ↑ | IL-18 | anti-inflammation | AOSD | ( |
PGE 2, prostaglandin E2; IL-10, interleukin-10; MKNK1, mitogen-activated protein kinase interacting serine/threonine kinase 1; NF-κB, nuclear factor kappa light-chain enhancer of activated B cells; SOD2, manganese superoxide dismutase, superoxide dismutase 2; VCAM-1, vascular cell adhesion molecule-1; TLR4, toll-like receptor 4; NLRP3, Nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain-containing 3; Th17, helper T cell 17; WNT, Wingless-Type MMTV Integration Site Family; CXCL2, Chemokine(C-X-Cmotif) ligand10; GM-CSF, granulocyte monocyte-colony stimulation factor; TRAF4, (TNF) tumor necrosis factor-receptor-associated factor 4; SP11, S-locusprotein 11; RAD51, a homologous recombination regulator homologous recombination; SLE, Systemic lupus erythematosus; COPD, chronic obstructive pulmonary disease; IBD, inflammatory bowel disease; AOSD, Adult-onset Still’s disease.
↑ Represents expression level rises.
↓ Represents expression level decreases.
Figure 3miRNA-mediated negative feedback loop of macrophage polarization to M1 type. TLR on the macrophage cell membrane, stimulated by bacterial LPS, activates NF-κB pathway, which in turn promotes the formation of miR-146a, and the formation of miR-146a inhibits NF-κB pathway by inhibiting IRAK1 and TRAF6. Expression and function are two distinct concepts for the same miRNA family members.
miRNAs regulate macrophage-involved chronic diseases.
| miRNA | Expression level | Target | Function | Chronic diseases | Ref. |
|---|---|---|---|---|---|
| miR-342-5p | ↑ | Akt1 | pro-inflammation | in early AS | ( |
| miR-155 | ↑ | CSF-1 | inhibit macrophage lesion | in early AS | ( |
| miR-92a | ↑ | KLF2 | pro-inflammation | in early AS | ( |
| miR-383 | ↓ | Parg | promote macrophage survival | in early AS | ( |
| miR-10a | ↑ | LCoR | promote lipid metabolism | in early AS | ( |
| miR-10b | ↑ | ABCA1 | reduclate plaque | in advanced AS | ( |
| miR-155 | ↑ | Bcl6 | pro-inflammation weaken efferocytosis | in advanced AS | ( |
| miR- 302a | ↑ | ABCA1 | promote lipid metabolism | in advanced AS | ( |
| miR-155 | ↑ | CEH | inhibit foam cell | AS | ( |
| miR-17-5p | ↓ | NF-κB | promote lipid metabolism | AS | ( |
| miR-34a | ↑ | ABCG1 liver X receptor α | pro-inflammation | AS | ( |
| miR-146a | ↑ | SOD2 | pro-inflammation | AS | ( |
| miR-140a | ↑ | IL-10 | pro-inflammation | AS | ( |
| miR-21-3p | ↑ | PTEN | promote tissue repair | AS | ( |
| miR-34a | ↑ | KLF4 | pro-inflammation promote insulin resistance | Obesity | ( |
| T2DM | |||||
| miR-210 | ↑ | NDUFA4 | promote insulin resistance | Obesity | ( |
| T2DM | |||||
| miR-690 | ↑ | Nadk | insulin sensitizer | Obesity | ( |
| T2DM | |||||
| miR-467a-5p | ↑ | THBS1 | prevent insulin resistance | Obesity | ( |
| T2DM | |||||
| miR-505-3p | ↓ | RUNX1 | pro-inflammation | Obesity | ( |
| T2DM | |||||
| miR-29 | ↑ | TRAF3 | pro-inflammation | Obesity | ( |
| T2DM | |||||
| miR-712 | ↓ | LRRK2 | anti-inflammation | Obesity | ( |
| T2DM | |||||
| miR-128-2 | ↑ | ABCA1 | promote lipid metabolism | Obesity | ( |
| ABCG1 | T2DM | ||||
| RXRa | |||||
| miR-33a | ↑ | ABCA1 | inhibit lipid metabolism | Obesity | ( |
| ABCG1 | T2DM | ||||
| miR-221-3p | ↓ | JAK3 | pro-inflammation | RA | ( |
| miR-29b | ↑ | HBP1 | pro-inflammation | RA | ( |
| miR-132 | ↑ | COX2 | promote osteoclastogenesis | RA | ( |
| miR-574-5p | ↑ | TLR 7/8 | promote osteoclastogenesis | RA | ( |
| miR-20a | ↑ | RANKL | inhibit osteoclastogenesis | RA | ( |
| miR-6089 | ↑ | TLR4 | inhibit osteoclastogenesis | RA | ( |
| miR-148a | ↓ | GP130 | pro-inflammation | IBD | ( |
| IKKα | |||||
| IKKβ | |||||
| IL1R1 TNFR2 | |||||
| miR-590-3p | ↑ | LATS1 | anti-inflammation promote tissue repair | IBD | ( |
| miR-378a-5p | ↑ | NLRP3 | anti-inflammation promote tissue repair | IBD | ( |
| miR-142-5p | ↑ | SOCS1 | promote fibrosis | liver cirrhosis | ( |
| miR-130a-3p | ↓ | PPARγ | promote fibrosis | liver cirrhosis | ( |
| miR-4512 | ↓ | TLR4 CXCL2 | pro-inflammation | SLE | ( |
| miR-20a | ↑ | IL-18 | anti-inflammation | AOSD | ( |
| miR-181b | ↑ | PKCδ | regulate macrophage polarization | Myocardial infarction | ( |
Akt1, serine/threonine protein kinase 1; CSF-1,colony-stimulating factor-1; KLF2,Krüppel-like factor 2; Parg, poly(ADP-ribose)-glycohydrolase; LCoR, ligand-dependent nuclear receptor corepressor; Bcl6, B-cell lymphoma 6 protein; RXRα, Retinoid X receptors α; ABCA1, ATP-binding cassette transporter A1; ABCG1, ATP-binding cassette subfamily G member 1; JAK3, Janus kinase 3 tyrosine-protein kinase; COX, Cyclooxygenase; IKK, inhibitor of nuclear factor kappa-B kinase; PTEN, phosphatase and tension homologue deleted from chromosome 10; KLF4, Krüppel-like factor 4; NDUFA4, NADH dehydrogenas, ubiquinone 1 alpha subcomplex 4; THBS1, thrombospondin 1; IL1R1, interleukin 1 receptor type 1; TNFR2, TNF receptor superfamily member 1b; TRAF3,TNF-receptor-associated factor 3; NF-κB, nuclear factor kappa light-chain enhancer of activated B cells; HBP1, the high-mobility group box-containing protein 1; TLR,Toll-like receptor; RANKL, receptor activation of nuclear factor-κB ligand; NLRP3, NOD-like receptor family, pyrin domain-containing 3; SOCS1,suppressor of cytokine signaling 1; PPARγ, peroxisome proliferator-activated receptor γ; PKCδ,protein kinase C δ; AS, atherosclerosis; T2DM, diabetes mellitus type 2; AR, rheumatoid arthritis; IBD, inflammatory bowel disease; SLE, Systemic lupus erythematosus; AOSD, Adult-onset Still’s disease.